U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

A group of Democratic senators are calling on Health and Human Services Secretary Robert F. Kennedy Jr. to keep a proposed ...

The Trump administration has decided not to go forward with a proposal for Medicare and Medicaid to cover high-demand obesity ...

Researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications.

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

The Trump administration announced Friday that it is not moving forward with a Biden-era proposal that would have expanded ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper ...

President Donald Trump’s administration has decided not to cover expensive, high-demand obesity treatments under the ...

A new guideline for treating obesity in children and adolescents says medication can be helpful, but that health providers ...

New evidence suggests that factors other than the percentage of weight loss should be considered when determining the success ...